Breast Cancer

Sacituzumab govitecan demonstrated an overall survival benefit vs physician's choice of treatment in patient with pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.

Patritumab deruxtecan displayed manageable safety and produced responses in heavily pretreated patients with estrogen receptor–positive or triple-negative metastatic breast cancer with varying levels of HER3 expression, according to data from a phase 2 study presented at the 2023 ASCO Annual Meeting.

A key opinion leader in breast cancer management shares insight on the treatment armamentarium for patients with HER2+ disease.

Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.

The triplet combination of zotatifin, abemaciclib, and fulvestrant demonstrated a confirmed overall response rate of 21% in heavily pretreated patients with estrogen receptor–positive metastatic breast cancer.

Findings from a subgroup analysis of the phase 3 EMERALD trial presented during the 2023 ASCO Annual Meeting demonstrated elacestrant elicited prolonged progression-free survival compared with standard-of-care therapy for patients with estrogen receptor-positive, HER2-negative non-detected ESR1 mutated breast cancer who experienced disease progression within 6 months of CDK4/6 inhibitor treatment plus endocrine therapy.

A clinically meaningful absolute risk reduction in invasive disease-free survival and distant relapse-free survival with abemaciclib plus endocrine therapy was maintained in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer regardless of age.

Colin E. Champ, MD, discusses the importance of considering the use of radiation therapy for patients with breast cancer and details ongoing research into this arena.

Treatment with ribociclib plus endocrine therapy led to a statistically and clinically meaningful improvement in invasive disease-free survival among patients with hormone receptor–positive/HER2-negative early breast cancer compared with endocrine therapy alone, meeting the primary end point of the phase 3 NATALEE trial.

Yuan Yuan, MD, PhD, discusses the importance of clinical trial participation and enrollment in patients with breast cancer.

Higher baseline HER3-positive circulating tumor cell count at baseline and reduction following treatment initiation was associated with a higher likelihood of deriving an early response with patritumab deruxtecan in patients with hormone receptor–positive or HER2-low advanced breast cancer.

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.

Sacituzumab govitecan-hziy displayed a manageable safety profile consistent with previous reports in patients with hormone receptor–positive, HER2-negative metastatic breast cancer, irrespective of UGT1A1 status, according to a safety analysis of the phase 3 TROPiCS-02 trial.

Christie J. Hilton, DO, discusses the potential impact of the ongoing phase 2 CompassHER2-pCR trial for patients with HER2-positive breast cancer.

Suzanne B. Coopey, MD, FACS, discusses the de-escalation of axillary lymph node surgery, shifts in the use of radiation oncology, and changes in the treatment paradigm for HER2-positive breast cancer.

Closing out his review of therapy for HER2+ metastatic breast cancer, Kevin Kalinsky, MD, MS, looks toward future evolutions in the treatment landscape.

Christie J. Hilton, DO, details the evolving role of trastuzumab deruxtecan in HER2-positive breast cancer and the potential to de-escalate therapy in early-stage disease.

Colin E. Champ, MD, discusses findings from 2 clinical trials investigating boost radiotherapy plus whole breast radiotherapy following surgery in patients with ductal carcinoma in situ or early-stage breast cancer.

A telephone and web-based weight loss intervention was successful in helping patients with breast cancer who were overweight or obese lose weight—which can ultimately lead to improved outcomes.

The National Comprehensive Cancer Network Guidelines now recommend the use of 18F-Fluorestradiol positron emission tomography in certain circumstances during the systemic staging workup for patients with recurrent or metastatic for estrogen receptor–positive breast cancer.

Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer.

The National Medical Products Administration has accepted the supplemental new drug application seeking the approval of toripalimab in combination with nab-paclitaxel in patients with untreated metastatic or recurrent triple-negative breast cancer and a PD-L1 combined positive score of at least 1.

The FDA has granted priority review to a new drug application seeking the approval of the optical imaging agent Lumisight for use in patients with breast cancer, according to an announcement from Lumicell, Inc.

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

A brief discussion on the role of trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer who progress on tucatinib therapy.